SU1605914A3 - Способ стабилизации высокоочищенного фактора некроза опухоли из плазмы или сыворотки кролика, индуцированного липополисахаридами - Google Patents
Способ стабилизации высокоочищенного фактора некроза опухоли из плазмы или сыворотки кролика, индуцированного липополисахаридами Download PDFInfo
- Publication number
- SU1605914A3 SU1605914A3 SU833571944A SU3571944A SU1605914A3 SU 1605914 A3 SU1605914 A3 SU 1605914A3 SU 833571944 A SU833571944 A SU 833571944A SU 3571944 A SU3571944 A SU 3571944A SU 1605914 A3 SU1605914 A3 SU 1605914A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- factor
- activity
- globulin
- protamine
- tumor
- Prior art date
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 7
- 239000002158 endotoxin Substances 0.000 title claims description 6
- 210000002966 serum Anatomy 0.000 title claims description 5
- 229920006008 lipopolysaccharide Polymers 0.000 title claims description 4
- 230000000087 stabilizing effect Effects 0.000 title description 4
- 206010054094 Tumour necrosis Diseases 0.000 title 1
- 230000001338 necrotic effect Effects 0.000 claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 102000006395 Globulins Human genes 0.000 abstract 5
- 108010044091 Globulins Proteins 0.000 abstract 5
- 102000007327 Protamines Human genes 0.000 abstract 5
- 108010007568 Protamines Proteins 0.000 abstract 5
- 229940048914 protamine Drugs 0.000 abstract 5
- 238000000746 purification Methods 0.000 abstract 3
- 238000000926 separation method Methods 0.000 abstract 3
- 230000003327 cancerostatic effect Effects 0.000 abstract 2
- 238000004108 freeze drying Methods 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 2
- 241000972773 Aulopiformes Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 235000019515 salmon Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 11
- 102000003390 tumor necrosis factor Human genes 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57129560A JPS5920225A (ja) | 1982-07-27 | 1982-07-27 | ガン壊死因子の安定化方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1605914A3 true SU1605914A3 (ru) | 1990-11-07 |
Family
ID=15012508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU833571944A SU1605914A3 (ru) | 1982-07-27 | 1983-04-05 | Способ стабилизации высокоочищенного фактора некроза опухоли из плазмы или сыворотки кролика, индуцированного липополисахаридами |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS5920225A (enrdf_load_stackoverflow) |
| SU (1) | SU1605914A3 (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2629000B2 (ja) * | 1986-07-18 | 1997-07-09 | 中外製薬株式会社 | 安定な顆粒球コロニー刺激因子含有製剤 |
| KR20220114183A (ko) * | 2021-02-08 | 2022-08-17 | 주식회사 대웅 | 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55108821A (en) * | 1979-02-14 | 1980-08-21 | Kanebo Ltd | Preparation of antitumor agent |
-
1982
- 1982-07-27 JP JP57129560A patent/JPS5920225A/ja active Granted
-
1983
- 1983-04-05 SU SU833571944A patent/SU1605914A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5920225A (ja) | 1984-02-01 |
| JPH0375530B2 (enrdf_load_stackoverflow) | 1991-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR860000842B1 (ko) | 종양 괴사 인자의 안정화 방법 | |
| US4824938A (en) | Water-soluble dry solid containing proteinaceous bioactive substance | |
| Zukin et al. | Properties of the galactose binding protein of Salmonella typhimurium and Escherichia coli | |
| JP2512453B2 (ja) | 天然のコロニ−促進因子―１の精製 | |
| EP0423244A1 (en) | TUMOR NECROSIS FACTOR FORMULATIONS. | |
| US3637640A (en) | Orgotein stabilized with saccharide process and products | |
| JPS59137417A (ja) | 人尿由来コロニ−形成刺激因子及びカリクレインの製造法 | |
| EP0090892B1 (en) | Process for the purification of physiologically active substance having antitumour activity | |
| US4124702A (en) | Polynucleotides active as inducers of interferon production in living animal cells | |
| JPH03505334A (ja) | 凍結乾燥されたペプチド製剤 | |
| US4529594A (en) | Protein having antitumor activity | |
| SU1605914A3 (ru) | Способ стабилизации высокоочищенного фактора некроза опухоли из плазмы или сыворотки кролика, индуцированного липополисахаридами | |
| JPH0713026B2 (ja) | 血友病ａ抑制患者の治療のための製剤及び該製剤の製造方法 | |
| US5532216A (en) | Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein | |
| JPS62185027A (ja) | 組換えインタ−ロイキン−２組成物およびその製造方法 | |
| JPH0222233A (ja) | スーパーオキシドディスムターゼ組成物 | |
| Russo et al. | Renal clearance of essential amino acids: threonine and phenylalanine | |
| EP0539408A1 (en) | STABILIZED COMPOSITION CONTAINING A FIBROBLAST GROWTH FACTOR. | |
| KR970009890B1 (ko) | 혈소판감소증치료제 | |
| Kim et al. | Immobilization of urokinase on agarose matrices | |
| JPS5959625A (ja) | ガン壊死因子を安定化する方法 | |
| JPH04198195A (ja) | Ｃｐｂ―ｉの安定化方法及び製剤組成物 | |
| US5998370A (en) | Agents for the prevention and/or treatment of radiation-induced disorders by administrating TCF-II | |
| JPH0375529B2 (enrdf_load_stackoverflow) | ||
| JPH04187640A (ja) | 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤 |